KMD Bioscience
Tianjin, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese CRO providing antibody discovery, proteomics, and diagnostic development services through multiple display platforms.
Infectious DiseaseOncologyImmunologyVeterinary
Technology Platform
Integrated antibody discovery platforms including phage display (scFv, Fab, VHH), yeast display, aptamer screening, and peptide library construction with capabilities in antibody humanization, production, and validation.
Opportunities
Growth in global demand for antibody discovery services, expansion into emerging modalities like aptamers and nanobodies, and leveraging China's growing biopharma sector for both domestic and international clients.
Risk Factors
Intense competition in the CRO space, rapid technological obsolescence of display platforms, potential intellectual property challenges, and geopolitical factors affecting international collaborations.
Competitive Landscape
Competes with global antibody discovery CROs like Creative Biolabs, Absolute Antibody, and GenScript, as well as specialized nanobody companies; differentiation through integrated multi-platform approach and focus on VHH/nanobody discovery.